BioAtla, Inc. (BCAB) Form 10-Q — Aug 13, 2026
BioAtla reported Q2 2026 collaboration revenue of $6.5 million from the amended Context Therapeutics license, producing net income of $452,000 versus an $18.7 million loss a year earlier. R&D expense fell to $3.3 million from $13.7 million after a 70% workforce reduction in March 2026. Management disclosed substantial doubt about the company's ability to continue as a going concern, with only $1.5 million in cash at June 30, 2026. The company launched a strategic alternatives process on March 2, 2026 and paused enrollment in its Phase 1 BA3182 trial while reassessing the BA3021 Phase 3 timeline.
Key figures
- Eps
- $0.27 Q2 2026; -$3.73 six months 2026
- Revenue
- $6.5 million (Q2 2026 collaboration revenue from the Context Amendment)
- Net Income
- Q2 2026 net income $452 thousand; six-month 2026 net loss $5.892 million (vs. $34.045 million prior-year six months)
- Total Assets
- $9.506 million
- Cash Position
- $1.544 million
- Shares Outstanding
- 1666100
- Sepa Commitment
- $15.0 million with Yorkville; $0.4 million drawn as of June 30, 2026
- Ga Expense Q2 2026
- $2.931 million vs. $4.963 million prior year
- Rd Expense Q2 2026
- $3.342 million vs. $13.684 million prior year
- Reverse Split Ratio
- 50:1 (effective April 6, 2026)
- Accumulated Deficit
- $551.5 million
- Stockholders Deficit
- $36.236 million
- Warrants Outstanding
- 193581
- Warrant Exercise Price
- $4.35 (repriced from $59.50 post-consolidation)
- Net Cash Used In Operations Six Months
- $5.686 million
Price after filing
Close on the filing date to close N calendar days later (from $3.45). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.